Microsoft Excel LibreOffice Calc

Eli Lilly & Co. (NYSE:LLY)

Income Statement
Quarterly Data

Beginner level

The income statement presents information on the financial results of a company’s business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Eli Lilly & Co., consolidated income statement (quarterly data)

US$ in thousands

Microsoft Excel LibreOffice Calc
3 months ended Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Revenue 5,859,800  6,114,000  5,476,600  5,636,700  5,092,200  6,438,600  6,061,900  6,355,200  5,700,000  6,160,700  5,658,000  5,824,300  5,228,300  5,760,500  5,191,700  5,404,800  4,865,100  5,375,600  4,959,700  4,978,700  4,644,700 
Cost of sales (1,215,100) (1,282,600) (1,175,000) (1,124,900) (1,138,700) (1,593,700) (1,562,300) (1,702,700) (1,571,300) (1,624,800) (1,566,100) (1,551,600) (1,327,700) (1,466,000) (1,400,900) (1,465,000) (1,323,000) (1,389,200) (1,236,900) (1,218,400) (1,192,700)
Gross margin 4,644,700  4,831,400  4,301,600  4,511,800  3,953,500  4,844,900  4,499,600  4,652,500  4,128,700  4,535,900  4,091,900  4,272,700  3,900,600  4,294,500  3,790,800  3,939,800  3,542,100  3,986,400  3,722,800  3,760,300  3,452,000 
Research and development (1,392,100) (1,581,400) (1,380,900) (1,402,200) (1,230,500) (1,453,800) (1,343,300) (1,333,100) (1,176,900) (1,473,200) (1,319,400) (1,250,900) (1,238,300) (1,450,600) (1,236,400) (1,335,900) (1,221,000) (1,444,200) (1,143,400) (1,169,500) (1,039,300)
Marketing, selling, and administrative (1,549,600) (1,698,100) (1,412,300) (1,586,300) (1,517,100) (1,861,500) (1,616,600) (1,653,700) (1,500,000) (1,780,500) (1,555,500) (1,707,400) (1,544,700) (1,790,100) (1,565,400) (1,622,600) (1,473,900) (1,798,400) (1,575,700) (1,635,400) (1,523,500)
Acquired in-process research and development (52,300) —  (77,700) (25,000) (136,900) (329,400) (30,000) (1,624,500) —  (50,000) (205,000) —  (857,600) (30,000) —  —  —  (199,000) —  (80,000) (256,000)
Asset impairment, restructuring, and other special charges (59,900) (151,700) —  —  (423,900) (246,000) (83,300) (74,400) (78,300) (1,003,200) (406,500) (50,000) (213,900) (147,600) (45,500) (58,000) (131,400) (144,900) (42,400) (72,400) (108,000)
Operating income (loss) 1,590,800  1,400,200  1,430,700  1,498,300  645,100  954,200  1,426,400  (33,200) 1,373,500  229,000  605,500  1,264,400  46,100  876,200  943,500  923,300  715,800  399,900  961,300  803,000  525,200 
Other, net, income (expense) 89,100  262,900  (24,900) (32,400) 86,000  (15,300) (15,400) 38,000  67,500  55,100  (13,900) (3,900) 15,100  15,800  27,200  21,200  (149,000) 44,700  86,500  (123,300) 92,700 
Income before income taxes 1,679,900  1,663,100  1,405,800  1,465,900  731,100  938,900  1,411,000  4,800  1,441,000  284,100  591,600  1,260,500  61,200  892,000  970,700  944,500  566,800  444,600  1,047,800  679,700  617,900 
Income taxes (223,400) (167,400) (151,900) (138,700) (170,000) 186,100  (261,500) (264,700) (223,600) (1,941,000) (36,000) (252,500) (172,000) (120,200) (192,700) (196,800) (126,700) 33,800  (248,100) (78,900) (88,400)
Net income (loss) from continuing operations 1,456,500  1,495,700  1,253,900  1,327,200  561,100  1,125,000  1,149,500  (259,900) 1,217,400  (1,656,900) 555,600  1,008,000  (110,800) 771,800  778,000  747,700  440,100  478,400  799,700  600,800  529,500 
Net income from discontinued operations —  —  —  —  3,680,500  —  —  —  —  —  —  —  —  —  —  —  —  —  —  —  — 
Net income (loss) 1,456,500  1,495,700  1,253,900  1,327,200  4,241,600  1,125,000  1,149,500  (259,900) 1,217,400  (1,656,900) 555,600  1,008,000  (110,800) 771,800  778,000  747,700  440,100  478,400  799,700  600,800  529,500 

Based on: 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-19), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-08-02), 10-Q (filing date: 2019-05-02), 10-K (filing date: 2019-02-19), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-07-25), 10-Q (filing date: 2018-04-27), 10-K (filing date: 2018-02-20), 10-Q (filing date: 2017-10-27), 10-Q (filing date: 2017-07-28), 10-Q (filing date: 2017-05-01), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-28), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-29), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-30), 10-Q (filing date: 2015-04-30).

Income statement item Description The company
Revenue Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Eli Lilly & Co.’s revenue increased from Q3 2019 to Q4 2019 but then slightly decreased from Q4 2019 to Q1 2020.
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Eli Lilly & Co.’s operating income (loss) decreased from Q3 2019 to Q4 2019 but then increased from Q4 2019 to Q1 2020 exceeding Q3 2019 level.
Income before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Eli Lilly & Co.’s income before income taxes increased from Q3 2019 to Q4 2019 and from Q4 2019 to Q1 2020.
Net income (loss) The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Eli Lilly & Co.’s net income (loss) increased from Q3 2019 to Q4 2019 but then slightly decreased from Q4 2019 to Q1 2020.